SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is drawing attention amid a volatile sector-wide biotech pullback and rebound, with traders debating whether the recent bounce signals stabilization or whether weakness will persist. The discussion links biotechs swings to rising-rate and risk-off concerns, while some see lower rates, sector rotation and M&A activity as potential supports.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is attracting attention ahead of its quarterly results, with traders debating whether weak branded-checkout trends and margin pressure could renew the stocks pattern of post-earnings declines, or whether subdued expectations and growth in Venmo and advertising could support a rebound. Takeover and bank-charter speculation also appears, but remains unconfirmed.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETRs sharp rebound has fueled short-squeeze and options-related speculation, with traders pointing to the companys share repurchases, a small float, and elevated short interest as potential pressure points. The squeeze is unconfirmed, and some traders question whether the rally can continue without stronger volume or further turnaround progress.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A rebound in Nasdaq and AI-linked tech after a sharp selloff has drawn attention to TQQQ, with traders split between viewing the move as a relief bounce with room to continue and warning it may be a bull trap. The funds 3x leverage amplifies the swings, fueling active options and technical trading amid uncertainty around the Fed and upcoming earnings.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos prolonged share-price slide is fueling concern about Eli Lillys competitive gains in the GLP-1 market and skepticism about managements execution and pipeline. Traders are split on whether recent licensing deals and oral Wegovy demand can support a recovery, with critics arguing the deals are too early-stage to address the competitive gap.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas quarterly earnings and outlook are driving discussion: despite a better-than-expected quarter and resilient payment volumes, traders focused on cautious growth guidance, higher expenses and workforce cuts as reasons for the muted reaction. Some see the results as evidence of a durable payments business, while others argue the beat was priced in and margins are under pressure.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports that Papa Johns largest U.S. franchisee joined Irth Capitals effort to take the company private are driving attention, reviving speculation about a potential sale. Traders are split between viewing the bid as a possible catalyst and doubting a deal will close, amid criticism of the board and concerns about weak sales and the turnaround.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat and new share-repurchase authorization were overshadowed by a narrowed full-year profit outlook, prompting a sharp selloff. Traders are split between viewing the decline as an overreaction given the cash-flow outlook and buyback, and seeing the guidance as a reason for caution.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Anticipation of Eli Lillys Q3 report is driving attention, with traders focused on whether Mounjaro and Zepbound demand can sustain growth and support the stocks run near record highs. Bulls point to Lillys strength in obesity drugs, while skeptics question whether expectations are too high and cite competition from Novo and the oral GLP-1 market.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Mixed Nielsen and scanner-sales reportsparticularly concerns about the core Celsius brand despite Alani Nu strengthare driving debate around growth and upcoming earnings. Bulls point to Alani Nu and expansion potential, while bears focus on core-brand weakness, competition and management execution; Pepsi buyout talk remains speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +39.58% and +30.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +12.93% and +2.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

Key PointsSamira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000...

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

Key Points15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share...

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Societys...

Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +63.04% and +32.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Corporation (LQDA) Surpasses Q1 Earnings and Revenue Estimates

Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +54.76% and +22.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -510.13% and -94.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of -48.03% and +1.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Septerna Inc.

Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled

Equity

Neutral Sentiment

Danish drug maker Novo Nordisk (NVO) on Tuesday announced an exclusive global collaboration and license agreement with U.S.-based Septerna, Inc. (SEPN) to discover, develop, and commercialise oral small-molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916006">said</a> the deal could be worth up to $2.2 billion. This includes more than $200 million in upfront and near-term milestone payments to Septerna and additional research, development, and commercial milestone payments.The California-based company is also eligible to receive tiered royalties on global net sales of marketed products.Novo Nordisk will cover all research and development expenses for partnered programs under the collaboration.The agreement is expected to close in the second quarter of 2025.The companies will initially commence four development programmes for potential small-molecule therapies directed at select G-protein-coupled receptor (GPCR) targets. GPCRs are a large and diverse family of cell membrane proteins involved in cellular communication.Septerna CEO Jeffrey Finer said that the collaboration provides an opportunity to create multiple oral medicines and provides the company with the operational flexibility and resources to advance its portfolio of other GPCR-targeted programmes.On Stocktwits, retail sentiment around Novo Nordisk fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours while message volume dropped from ‘extremely high’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:629/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_14_at_8_28_57_AM_png_13db4d5cfd.webp" alt="Screenshot 2025-05-14 at 8.28.57 AM.png" width="629" height="64"><figcaption>NVO's Sentiment Meter and Message Volume as of 8:30 a.m. ET on May 14, 2025 | Source: Stocktwits</figcaption></figure> Meanwhile, retail sentiment on Septerna jumped from ‘bearish’ to ‘extremely bullish’ territory while message volume jumped from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_14_at_8_31_56_AM_png_a149898af9.webp" alt="Screenshot 2025-05-14 at 8.31.56 AM.png" width="628" height="62"><figcaption>SEPN's Sentiment Meter and Message Volume as of 8:35 a.m. ET on May 14, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed concerns about the new agreement, opining that Septerna’s pipeline is in the “early stage.”<stembedurl>https://stocktwits.com/NEVER_SAY_TRANSITORY/message/614571231</stembedurl>However, another investor expressed optimism on the stock if it breaks the $12.40 mark.<stembedurl>https://stocktwits.com/Trad3Slinger/message/614572114</stembedurl><a href="https://stocktwits.com/symbol/SEPN">SEPN stock</a> is up by about 70% in premarket trading on Wednesday.The stock is down by 68% this year and nearly 69% over the past 12 months.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a>, meanwhile, is trading nearly 3% higher in pre-market.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-backed-databricks-acquires-database-startup-neon/chiqpslRbNL">Nvidia, Microsoft-Backed Databricks Bets Big On AI Agents With $1B Neon Takeover: Retail Turns Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Septerna CEO Jeffrey Finer said that the collaboration allows the company to create multiple oral medicines and provides the operational flexibility and resources to advance its portfolio of other GPCR-targeted programmes.

$HOOD (Tuesday afternoon)

$MSFT (Wednesday afternoon)

$GOOGL (Wednesday afternoon)

$AMZN (Thursday afternoon)

Which earnings release are you most excited for this week?

Drop a comment for other tickers.

Current Price	$41.38
Prev Close	$40.41
Open	$40.42
Dividend Yield	0.00%
50-Day Moving Average	$38.86
Beta	1.28
Avg. Volume	333,660.69
PE Ratio	-76.07

52-Week High	$51.10
52-Week Low	$17.55
Market Capitalization	$1.89B
EPS (Annual)	-$1.10
Price to Book	4.89
Revenue Per Employee	$353,469.23

Feed

News

Sentiment

Earnings

Fundamentals

Info

SEPN Fundamentals